New insights into mechanisms of blood pressure regulation in patients with uraemia
Authors:
Open Access
- 1 January 1996
- journal article
- review article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 11 (supp2) , 52-59
Abstract
There is no doubt that in patients with end-stage renal failure sodium/water retention and (often unrecognized) hypervolaemia is the single most important determinant for elevated blood pressure. More detailed analysis reveals that in the renal patient susceptibility to hypervolaemia is increased due to inappropriately elevated activity of pressor systems (and/or decreased activity of depressor systems). These abnormalities comprise inappropriately activated reninangiotensin system (RAS) (circulating and local) as well as sympathetic activity, but more hypothetical possibilities must also be considered, e.g. abnormalities of renal vasodilators (medullipin), L-arginine-derived agmatin, endothelin and NO.Keywords
This publication has 41 references indexed in Scilit:
- Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failureThe Lancet, 1992
- ANALGESIC ABUSE AND HYPERTENSIONThe Lancet, 1989
- Arterial hypotension in chronic hemodialyzed patientsKidney International, 1987
- The importance of plasma protein for blood volume and blood pressure homeostasisKidney International, 1986
- Plasma free, sulfo- and glucuro-conjugated catecholamines in uremic patientsKidney International, 1986
- Norepinephrine-related mechanism in hypertension accompanying renal failureKidney International, 1985
- Diminished vascular response to noradrenaline in experimental chronic uremiaKidney International, 1982
- Mechanisms of autonomic nervous system dysfunction in uremiaKidney International, 1981
- Hypertension in terminal renal failureKidney International, 1976
- RENIN SECRETION IN RENAL HYPERTENSIONThe Lancet, 1970